Personalis, Inc. (PSNL): Price and Financial Metrics
PSNL Price/Volume Stats
| Current price | $1.21 | 52-week high | $2.74 |
| Prev. close | $1.20 | 52-week low | $0.89 |
| Day low | $1.18 | Volume | 288,500 |
| Day high | $1.27 | Avg. volume | 386,487 |
| 50-day MA | $1.43 | Dividend yield | N/A |
| 200-day MA | $1.53 | Market Cap | 61.11M |
PSNL Stock Price Chart Interactive Chart >
Personalis, Inc. (PSNL) Company Bio
Personalis, Inc. provides genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.
Latest PSNL News From Around the Web
Below are the latest news stories about PERSONALIS INC that investors may wish to consider to help them evaluate PSNL as an investment opportunity.
Even With A 37% Surge, Cautious Investors Are Not Rewarding Personalis, Inc.'s (NASDAQ:PSNL) Performance CompletelyPersonalis, Inc. ( NASDAQ:PSNL ) shares have had a really impressive month, gaining 37% after a shaky period... |
Personalis Extends Cash Position Into 2026, Provides Update on Key InitiativesFREMONT, Calif., December 04, 2023--Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), disclosed a reduction in headcount impacting approximately 20% of the company’s staff. By consolidating several functions for efficiency, this reduction is expected to reduce operating expenses by approximately $14 million annually. This action, along with the recently announced Tempus collaboration, is expected to extend the cash position of the company into 2026. |
Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer TestingFREMONT, Calif. & CHICAGO, November 28, 2023--Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), and Tempus Labs, Inc., a leader in artificial intelligence and precision medicine, today announced a strategic collaboration to co-commercialize NeXT Personal® Dx, Personalis’ whole genome-based liquid biopsy laboratory developed test (LDT) for detection of molecular residual disease (MRD) and recurrence in cancer. NeXT Personal Dx is a leap forward in tumor-inform |
Meet the biotech company Cathie Wood bought half a million shares of this monthCathie Wood founded Ark Invest in 2014 to provide investors exposure to what she calls "disruptive innovation," a strategy that encompasses artificial intelligence, energy storage, blockchain technology, robotics and gene editing. While Ark's flagship Innovation ETF is largely exposed to Wood's chosen AI and cryptocurrency plays, Ark has invested plenty of capital into a variety of biotech firms across its funds. |
Personalis, Inc. (NASDAQ:PSNL) Q3 2023 Earnings Call TranscriptPersonalis, Inc. (NASDAQ:PSNL) Q3 2023 Earnings Call Transcript November 7, 2023 Personalis, Inc. beats earnings expectations. Reported EPS is $-0.48, expectations were $-0.54. Operator: Good afternoon and welcome to Personalis Third Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode. [Operator instructions] After today’s prepared remarks there will be an opportunity […] |
PSNL Price Returns
| 1-mo | -19.87% |
| 3-mo | -19.33% |
| 6-mo | 27.69% |
| 1-year | -50.81% |
| 3-year | -94.27% |
| 5-year | N/A |
| YTD | -42.38% |
| 2023 | 6.06% |
| 2022 | -86.12% |
| 2021 | -61.02% |
| 2020 | 235.87% |
| 2019 | N/A |
Loading social stream, please wait...